Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 4/20 | 0.36 |
| ▸ | ATM | Q13315 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2182836 | 0.91 | POLB (0.43) | MEN1KMT2AL3MBTL1CTSKPOLB | |
| SCHEMBL2182884 | 0.88 | ADORA2A (0.38) | MEN1KMT2AADORA2APIK3CAADORA2B | |
| SCHEMBL2181754 | 0.87 | ADORA2A (0.37) | MTORATMMEN1KMT2AADORA2A | |
| SCHEMBL2181516 | 0.87 | ADORA2A (0.37) | MEN1KMT2AADORA2APIK3CAADORA2B | |
| SCHEMBL2182767 | 0.86 | POLB (0.43) | MEN1KMT2AADORA2AADORA3POLB | |
| SCHEMBL2181108 | 0.85 | ADORA2A (0.38) | MEN1KMT2AADORA2AADORA2BLMNA | |
| SCHEMBL2184114 | 0.85 | ADORA2A (0.36) | MTORATMCTSKADORA2APOLB | |
| SCHEMBL2182538 | 0.85 | ADORA2A (0.36) | ADORA2AJAK2JAK1JAK3 | |
| SCHEMBL2182971 | 0.85 | POLB (0.39) | MTORATMMEN1KMT2AL3MBTL1 | |
| SCHEMBL2181572 | 0.84 | ADORA2A (0.36) | ATMCTSKADORA2APIK3CAADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166144-A1 | Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166144-A1 | Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same | DPYD, TYMP, DHFR | MTOR 2329/4885ATM 1302/4885MEN1 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.